Spots Global Cancer Trial Database for Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer
Official Title: A Phase II Study of Single Agent OSI-7904L In Patients With Locally Advanced or Metastatic Adenocarcinoma Of the Stomach or Gastroesophageal Junction
Study ID: NCT00073502
Interventions
Study Description
Brief Summary: Multi-center, open-label, non-randomized Phase II study to evaluate the efficacy and safety of OSI-7904L in gastric and GEJ cancers. Those patients who do not derive clinical benefit after two cycles may be switched to a commonly used combination regimen.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
MD Anderson Cancer Center, Houston, Texas, United States
University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States
Dept Internal Medicine Gastrointestinal Oncology Unit, B-3000 Leuven, , Belgium
Bristol Haematology & Oncology Centre, Bristol, Avon, United Kingdom
ICRF Medical Oncology Unit, Oxford, Oxfordshire, United Kingdom
Deanesly Centre, Wolverhampton, West Midlands, United Kingdom
NICCTU, East Podium, C-Floor, Belfast, , United Kingdom
Beatson Oncology Centre, Glasgow, , United Kingdom
Cookridge Hospital, Leeds, , United Kingdom
Department of Medical Oncology, Manchester, , United Kingdom
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
